On or around 11/25/2020 (Date of last review)
Filing Date: August 17, 2020
According to the Complaint, Chembio Diagnostics, Inc. describes itself as a leading point-of-care diagnostics company focused on detecting and diagnosing infectious diseases.
Throughout the Section 10(b) Class Period, the Company represented that its DPP COVID-19 serological POC test for the detection of IgM and IgG antibodies aided in determining current or past exposure to the COVID-19 virus, that its test provides high sensitivity and specificity, and was 100% accurate. The Complaint alleges that those statements were false and misleading, and that Plaintiffs and other Class members have suffered significant losses and damages as a result of Defendants’ false and misleading statements of fact and omissions of material facts.
Company & Securities Information
Defendant: Chembio Diagnostics, Inc.
Industry: Biotechnology & Drugs
Headquarters: United States
Ticker Symbol: CEMI
Company Market: NASDAQ
Market Status: Public (Listed)
About the Company & Securities Data
"Company" information provides the industry and sector classification and headquarters state for the primary company-defendant in the litigation. In general, "Securities" information provides the ticker symbol, market, and market status for the underlying securities at issue in the litigation.
In most cases, the primary company-defendant actually issued the securities that are the subject of the litigation, and the securities information and company information relate to the same entity. In a small subset of cases, however, the primary company-defendant is not the issuer (for example, cases against third party brokers/dealers), and the securities information and company information do not relate to the same entity.
First Identified Complaint
Special Situations Fund III QP, L.P., et al. v. Chembio Diagnostics, Inc., et al.